drugset
drugset / Trial / NCT05137600

A Drug-Drug Interaction Study Between ATI-2173 and Midazolam or Clarithromycin in Healthy Subjects

NCT05137600 ↗

Phase 1 Completed 36 enrolled Antios Therapeutics, Inc
Non-randomizedSequentialOpen-labelTreatment

Summary

This study is a single-center, open-label, 2-cohort, fixed-sequence, DDI study in healthy adult subjects. Healthy volunteers will be administered multiple oral doses of ATI-2173 in combination with midazolam or clarithromycin and assessed for safety and tolerability including blood tests to show how the body metabolizes and eliminates the investigational drug as well as how the investigational drug interacts with midazolam or clarithromycin.

Timeline

Start
2021-10-28
Primary completion
2021-12-23
Completion
2022-01-23

Drugs

EvaluationDrugModalityDoseRoute
Subject Clarithromycin Small molecule — —
Subject FOSCLEVUDINE ALAFENAMIDE Other / unclassified 50 mg Oral
Subject Midazolam Small molecule — —

Indications

No indication recorded.